<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04142112</url>
  </required_header>
  <id_info>
    <org_study_id>OHANA-IVF-001</org_study_id>
    <nct_id>NCT04142112</nct_id>
  </id_info>
  <brief_title>Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation</brief_title>
  <acronym>SPRING</acronym>
  <official_title>A Randomized, Blinded, Standard-Controlled, Study to Evaluate the Safety and Efficacy of Ohana In-Vitro Fertilization (IVF) Sperm Preparation Kit OHB035 on IVF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohana BioSciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohana BioSciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-centered, randomized controlled study, evaluating the safety and efficacy of the Ohana&#xD;
      IVF Sperm Preparation Kit vs. a standard IVF sperm preparation kit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This blinded, randomized, standard-controlled, paired study will be performed in&#xD;
      approximately 83 healthy couples (pairs of male and female subjects), who are appropriate&#xD;
      candidates for IVF in six fertility centers located in the United States (US).&#xD;
&#xD;
      The study will capture the selection of the best embryo for transfer and follow-up on&#xD;
      pregnancy outcomes that result from the transfer of the selected embryo following the IVF&#xD;
      procedure, and the results of safety assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">July 26, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 26, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blastocyst Evaluation</measure>
    <time_frame>Three months following last patient treated.</time_frame>
    <description>To compare the difference in the number of high-quality euploid blastocysts per mature oocyte in subjects undergoing split IVF insemination using sperm prepared with Ohana IVF sperm preparation kit OHB035 (OHANA) versus sperm prepared using a Standard IVF sperm preparation kit OHB037 (STANDARD)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>Infertility</condition>
  <condition>Infertility, Male</condition>
  <arm_group>
    <arm_group_label>Ohana IVF Sperm Preparation Kit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Samples in the Ohana IVF Sperm Preparation Kit group will undergo product-specific multistep processing in the lab prior to insemination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard IVF Preparation Kit</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Samples in the Standard IVF Sperm Preparation Kit group will undergo traditional processing in the lab prior to insemination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ohana IVF Sperm Preparation Kit (OHB035)</intervention_name>
    <description>The Ohana IVF Sperm Preparation Kit (OHB035) contains media for processing sperm through a series of timed steps prior to insemination with oocytes.</description>
    <arm_group_label>Ohana IVF Sperm Preparation Kit</arm_group_label>
    <other_name>Ohana</other_name>
    <other_name>OHB-035</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard IVF Preparation Kit (OHB037)</intervention_name>
    <description>The Standard IVF Sperm Preparation Kit (OHB037) contains media for processing sperm per the traditional steps prior to insemination with oocytes.</description>
    <arm_group_label>Standard IVF Preparation Kit</arm_group_label>
    <other_name>Standard</other_name>
    <other_name>OHB-037</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria: (Sample)&#xD;
&#xD;
        Female Inclusion Criteria:&#xD;
&#xD;
          1. Premenopausal, age 25-37 years at the time of providing informed consent, who is an&#xD;
             appropriate candidate for IVF.&#xD;
&#xD;
          2. Infertility for â‰¥ 12 months with regular intercourse with current male partner (or &gt;6&#xD;
             months if age &gt;35).&#xD;
&#xD;
          3. Regular menses defined as 25 to 35-day cycles or an average of 10-13 spontaneous&#xD;
             menstrual periods per year without exogenous hormones.&#xD;
&#xD;
          4. AMH between 1.8 - 4.9 ng/ml based on screening measurement at central laboratory.&#xD;
&#xD;
          5. AFC &gt;14 within 3 months of screening visit.&#xD;
&#xD;
        Male Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide semen specimens at the Screening Visit and on the day of&#xD;
             oocyte retrieval; (the specimen provided must be suitable for conventional IVF).&#xD;
&#xD;
          2. Provide a semen specimen with at least 4 million total motile sperm, following density&#xD;
             gradient centrifugation and washing of the sample, at the Screening Visit.&#xD;
&#xD;
        Exclusion Criteria: (Sample)&#xD;
&#xD;
        Female Exclusion Criteria:&#xD;
&#xD;
          1. Recurrent pregnancy loss (defined as &gt;2 clinical pregnancies without live birth).&#xD;
&#xD;
          2. Contraindications to being pregnant or to any of the IVF hormonal modulating&#xD;
             medications to be used in this study.&#xD;
&#xD;
          3. History of severe ovarian hyperstimulation syndrome (OHSS) requiring medical or&#xD;
             surgical intervention.&#xD;
&#xD;
          4. Clinically diagnosed polycystic ovarian syndrome (PCOS.)&#xD;
&#xD;
          5. Gynecologic history of: pelvic surgery (prior diagnostic or nonoperative laparoscopy,&#xD;
             hysteroscopy or operative hysteroscopy are allowed.&#xD;
&#xD;
          6. Tobacco or nicotine use in the past 12 months.&#xD;
&#xD;
          7. History of substance abuse, including alcohol abuse.&#xD;
&#xD;
          8. Abnormal, undiagnosed, vaginal bleeding at the time of screening.&#xD;
&#xD;
        Male Exclusion Criteria:&#xD;
&#xD;
          1. History of: vasectomy or vasectomy reversal.&#xD;
&#xD;
          2. Inability and/or unwillingness to provide semen specimens.&#xD;
&#xD;
          3. Tobacco or nicotine use in the past 12 months.&#xD;
&#xD;
          4. History of substance abuse, including alcohol abuse.&#xD;
&#xD;
          5. Marijuana use in the past 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fertility Treatment Center</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Medical Research Group, LLC</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shady Grove Fertility</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston IVF Fertility Clinic</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Conceptions, P.A.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Main Line Fertility Center</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Assisted Reproduction</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 25, 2019</study_first_submitted>
  <study_first_submitted_qc>October 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>September 4, 2020</last_update_submitted>
  <last_update_submitted_qc>September 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data collected from this study will be pooled. The study size would not allow for statistical analysis on a site by site level.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

